TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Processa Pharmaceuticals ( (PCSA) ).
On July 1, 2025, Processa Pharmaceuticals announced a strategic portfolio review and pipeline realignment to maximize shareholder value. The company has signed a binding term sheet with Intact Therapeutics for licensing PCS12852, is enrolling patients in a Phase 2 study of PCS6422, and has strengthened its balance sheet with a $7 million capital infusion. The company is focusing on oncology assets with strong differentiation and commercial opportunity, aiming to optimize resources and expedite asset value unlocking through partnerships. Processa is also designing a new Phase III study for PCS499 and has terminated the license agreement for PCS3117 due to high costs and time requirements.
The most recent analyst rating on (PCSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Underperform.
Processa Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing losses. Technical indicators point to bearish momentum, and valuation metrics highlight the high-risk nature typical of early-stage biotech firms. The company’s reliance on external financing for sustainability remains a concern.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing next-generation cancer drugs with improved safety and efficacy. The company modifies existing FDA-approved oncology therapies to enhance metabolism and distribution while maintaining cancer-killing mechanisms. Processa’s strategy involves combining its novel oncology pipeline with proven active molecules and a Regulatory Science Approach to create more effective and tolerable cancer therapies. Additionally, Processa seeks strategic partnerships for non-oncology assets to unlock further value.
Average Trading Volume: 18,259,040
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.14M
See more insights into PCSA stock on TipRanks’ Stock Analysis page.